Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
9
imaging with CuATSM
Imaging with CuATSM
Imaging with CuATSM
imaging with CuATSM
Imaging with CuATSM
Imaging with CuATSM
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
To validate the CuATSM-PET imaging by correlation to the serum level of osteopontin, a marker of hypoxia
Time frame: end of study
To test reliability of the CuATSM uptake by quantifying the reproducibility of the pre-treatment CuATSM_PET scans
Time frame: end of study
To assess the technical and logistic feasibility of CuATSM-PET scans in a population of cancer patients
Time frame: end of study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.